A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Clinical trial NCT07227597 · RECRUITING

Trial details

NCT number: NCT07227597
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer Extensive Stage

Start date: 2026-01-29
Primary completion: 2030-11-29
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.